Matinas BioPharma Holdings Inc (FRA:6LJ0)
€ 2.69 0 (0%) Market Cap: 2.89 Mil Enterprise Value: -4.57 Mil PE Ratio: 0 PB Ratio: 0.19 GF Score: 53/100

Matinas BioPharma Holdings Inc To Discuss EnACT Topline Data Call Transcript

Sep 13, 2021 / 12:00PM GMT
Release Date Price: €34 (+4.62%)
Operator

Hello, and welcome to the Matinas BioPharma EnACT trial conference call and webcast. (Operator Instructions)

As a reminder, this call is being recorded. I will now turn the conference over to Peter Vozzo, Investor Relations representative for Matinas BioPharma. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Kevin. Good morning, everyone, and thank you for joining the Matinas BioPharma EnACT Trial Conference Call. Speaking on today's call from Matinas will be Jerry Jabbour, Chief Executive Officer; Dr. Terri Matkovits, Chief Development Officer; and Dr. Terry Ferguson, Chief Medical Officer. We also have Dr. David Boulware, Professor of Medicine, Infectious Disease and International Medicine, University of Minnesota Medical School and co-principal investigator of the EnACT trial, on the call to provide his perspectives on the data. Finally, Dr. Raphael Mannino, Chief Scientific Officer of Matinas, will also be on the call and participating in the question-and-answer session.

For those of you participating via conference

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot